Résumé
OBJECTIVE: To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC). METHODS: One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed. RESULTS: The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group. CONCLUSION: Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.
Résumé
Objective: To determinate the content of bufalin,resibufogenin and cinobufagin in Cinobufacini Injection. Methods: Liposoluble components in cinobufacini were extracted with ethyl acetate and determined by HPLC using a C 18 column, acetonitrile water(50∶50) as a mobile phase and UV detection wavelength at 299nm. Results: The method showed the good resolution, high sensitivity, satisfactory accuracy and specificity. Quantitatively analyze results showed that the concentration of bufalin, cinobufagin and resibufogenin in Cinobufacini Injection were 0.333 ?g?mL -1 , 0.159?g?mL -1 and 0.110?g?mL -1 , respectively. Conclusion: Bufalin in Cinobufacini Injection reached effective concentration, which was regarded as one of anti cancer components.